These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27688014)

  • 1. Fortifying p53 - beyond Mdm2 inhibitors.
    Sriraman A; Li Y; Dobbelstein M
    Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
    [No Abstract]   [Full Text] [Related]  

  • 2. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
    Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance acquisition to MDM2 inhibitors.
    Cinatl J; Speidel D; Hardcastle I; Michaelis M
    Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21
    Lee J; Kim J; Kim EM; Kim U; Kang AR; Park JK; Um HD
    Biochem Biophys Res Commun; 2021 Mar; 543():23-28. PubMed ID: 33503543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 inhibitors for pancreatic cancer therapy.
    Azmi AS; Philip PA; Almhanna K; Beck FW; Sarkar FH; Mohammad RM
    Mini Rev Med Chem; 2010 Jun; 10(6):518-26. PubMed ID: 20377522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical reactivation of p53 pathways in cancer.
    Azmi AS
    Curr Pharm Des; 2011; 17(6):534-5. PubMed ID: 21391903
    [No Abstract]   [Full Text] [Related]  

  • 11. Model-based optimization of combination protocols for irradiation-insensitive cancers.
    Hat B; Jaruszewicz-Błońska J; Lipniacki T
    Sci Rep; 2020 Jul; 10(1):12652. PubMed ID: 32724100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability.
    Lu X; Nguyen TA; Zhang X; Donehower LA
    Cell Cycle; 2008 Jan; 7(2):164-8. PubMed ID: 18333294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy].
    Kamada R; Chuman Y; Kozakai Y; Sakaguchi K
    Seikagaku; 2015 Oct; 87(5):531-8. PubMed ID: 26638620
    [No Abstract]   [Full Text] [Related]  

  • 20. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.